Duality Advisers’s Esperion Therapeutics ESPR Stock Holding History

Duality Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-42,213	Closed	-$509K	–	550
2021 Q3	$509K	Buy	+42,213	New	+$615K	0.04%	445

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Duality Advisers's ESPR Position: Q4 2021 in Review

Duality Advisers sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 42,213 shares — an estimated $509K sold.

Duality Advisers first reported a position in ESPR in Q3 2021 and held it in 1 quarter. The position peaked at $509K in Q3 2021. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

Duality Advisers reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
Duality Advisers sold 42,213 Esperion Therapeutics shares in Q4 2021, an estimated $509K.
Duality Advisers first reported a position in Esperion Therapeutics in Q3 2021 and held it in 1 quarter.
Duality Advisers's Esperion Therapeutics position peaked at $509K in Q3 2021.
133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on Duality Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.